document.write("
05\/31\/2019 - Talking to your clinical trial data \/ Clinical trial budget bickering\/ Ireland ratchets up clinical research<\/a><\/div>
05\/24\/2019 - Clinical trials market explodes\/ Google forays into clinical trials\/ demise of small sites?<\/a><\/div>
05\/17\/2019 - How are the sites faring?\u00a0 An interview.<\/a><\/div>
05\/10\/2019 - AI and clinical trials, new cancer drugs not necessarily better, "the funding effect"<\/a><\/div>
05\/03\/2019 - New FDA Guidance; Pipelines & Patients; Can blood samples replace biopsies?<\/a><\/div>
04\/12\/2019 - Immune age, biomarkers, & duration of effect in trial design<\/a><\/div>
04\/05\/2019 - Cost of trials varies around the globe<\/a><\/div>
03\/21\/2019 - New FDA Guidance \/ AI in clinical trials \/ investigator selection<\/a><\/div>
03\/08\/2019 - Changes coming to FDA review process \/ Clinical trials bot \/ "Digital skin"<\/a><\/div>
03\/01\/2019 - 5 biotech stocks to buy now \/ can Flatiron change the clinical trial model?<\/a><\/div>
02\/22\/2019 - JP Morgan recap \/ New NASH treatment? \/ Site woes<\/a><\/div>
02\/15\/2019 - New FDA guidance \/ CRA burnout survey \/ famous trial failures<\/a><\/div>
02\/08\/2019 - New FDA Guidance \/ Synthetic control group design \/ CRA burnout<\/a><\/div>
02\/01\/2019 - Medical marijuana \/ Australia GCP reforms \/ stiff exclusion criteria<\/a><\/div>
01\/18\/2019 - Festival of Biologics; new ASCO statements; gene therapy<\/a><\/div>
01\/11\/2019 - Senolytics \/ FDA Guidance on patient experience \/ bureaucracy<\/a><\/div>
12\/21\/2018 - Industry mega-trends \/ 3 wishes \/ List of AI R&D companies<\/a><\/div>
12\/14\/2018 - Australia trials \/ FDA sued \/ AI & Blockchain in clinical trials<\/a><\/div>
12\/07\/2018 - NCI: We need to modernize cancer clinical trials<\/a><\/div>
11\/30\/2018 - FDA to target "quality control" activities in clinical trials<\/a><\/div>
11\/16\/2018 - Meta-analysis, competence standards, cancer drug harms downplayed<\/a><\/div>
11\/02\/2018 - Lucrative drug trials, informed consent violations, FDA promotes surrogate endpoints<\/a><\/div>
10\/26\/2018 - Hybrid clinical trials, docs frustrated, blockchain & clinical trials<\/a><\/div>
10\/19\/2018 - New FDA clinical research guidance; transparency rules impinge on ability to patent trial inventions<\/a><\/div>
10\/12\/2018 - Too many immunotherapy trials; new AD prevention study; drug study leaves UK<\/a><\/div><\/div>");